catridecacog catridecacog catridecacog, sold under the brand name tretten in the us and novothirteen in the eu) is a class of recombinant factor xiii a-subunit based biopharmaceutical medicine, indicated in patients with a rare clotting disorder, congenital factor xiii a-subunit deficiency, which is a kind of factor xiii deficiency. the medication prevents bleeding in patients with this condition, and has been approved by the u.s. food and drug administration (fda) for this use in the us in 2014. it was brought to market by novo nordisk. catridecacogclinical datatrade namestretten, novothirteenahfs/drugs.commonographlicense data eu ema: by inn us dailymed: catridecacog pregnancycategory au: b2 routes ofadministrationinjectionatc codeb02bd11 (who) legal statuslegal status au: unscheduled us: ℞-only eu: rx-only identifierscas number606138-08-3drugbankdb09310chemspidernoneuniinu23q531g1keggd10532chemblchembl2108282